ZURA BIO LIMITED Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ZURA BIO LIMITED (ZURA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $95.73 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-11
- ZURA BIO LIMITED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $116.19M.
- ZURA BIO LIMITED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$5.93M.
- ZURA BIO LIMITED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$9.99M, a 123.56% decline year-over-year.
- ZURA BIO LIMITED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $42.40M.
- ZURA BIO LIMITED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$67.09M, a 187.48% decline from fiscal 2024.
- ZURA BIO LIMITED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $76.69M, a 21.93% decline from fiscal 2023.
- ZURA BIO LIMITED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $98.24M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 2 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 5 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 8 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 11 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $95.73K 10-Q · filed 2026-08-11 | ||||||||
| 2026-03-31 | $116.19M 10-Q · filed 2026-05-07 | ||||||||
| 2025-12-31 | -$67.09M 10-K · filed 2026-03-19 | ||||||||
| 2025-09-30 | -$37.48M 10-Q · filed 2025-11-13 | ||||||||
| 2025-06-30 | -$22.01K 10-Q · filed 2026-08-11 | -$22.01M 10-Q · filed 2025-08-14 | |||||||
| 2025-03-31 | -$5.93M 10-Q · filed 2026-05-07 | ||||||||
| 2024-12-31 | $76.69M 10-K · filed 2026-03-19 | ||||||||
| 2024-09-30 | $88.42M 10-Q · filed 2025-11-13 | ||||||||
| 2024-06-30 | $88.64M 10-Q · filed 2025-08-14 | ||||||||
| 2024-03-31 | -$9.99M 10-Q · filed 2025-05-08 | ||||||||
| 2023-12-31 | $98.24M 10-K · filed 2025-03-25 | ||||||||
| 2023-09-30 | $102.29M 10-Q · filed 2024-11-07 | ||||||||
| 2023-06-30 | $111.23M 10-Q · filed 2024-08-13 | ||||||||
| 2023-03-31 | $42.40M 10-Q · filed 2024-05-09 | ||||||||
| 2022-12-31 | $1.57M 10-K · filed 2024-03-28 | ||||||||
| 2022-09-30 | $3.05M 10-Q · filed 2023-11-13 | ||||||||
| 2022-06-30 | $4.41M 10-Q · filed 2023-08-14 | ||||||||
| 2022-03-31 | $4.72M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |